| Literature DB >> 36251123 |
Debmitra Sen1,2, Sutripta Sarkar3, Poulami Mukhopadhyay4.
Abstract
Prime Editing is a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) based genome editing technique having promising potential in terms of reducing off target activity. It introduces fragments of DNA sequences into the target site using a guide RNA (gRNA) molecule, composed of both the sequence that is to be inserted into the target site along with an inactive Cas9 nickase and a reverse transcriptase. Prime Editing can cause insertions, deletions, and various point mutations for reverting the phenetic characteristics of a disease specially tested in human adult stem cells and cancer cell lines. The main aim of our review is to explore how Prime Editing and its various forms are being utilized as an emerging tool to cure deleterious diseases like cancer, also as a delivery strategy of the tool into cells. There are almost five generations of Prime Editors (PE) with increasing levels of efficiency from one level to another that have huge clinical potential in correcting mutations; however, the necessity for a pegRNA design is extremely significant. But besides having such advantages, the limitations of this technology particularly include generation of double nicks while optimizing the efficiency of PE3. So, it is important to consider all such consequences and customize PE as per requirements.Entities:
Keywords: CRISPR; Cancer; Prime Editing; Prime Editors; pegRNA
Year: 2022 PMID: 36251123 PMCID: PMC9574179 DOI: 10.1007/s12033-022-00580-3
Source DB: PubMed Journal: Mol Biotechnol ISSN: 1073-6085 Impact factor: 2.860
Fig. 1Basic mechanism of Prime Editing
Functional features of the Prime Editors—PE1, PE2, PE3
| Sl no | Prime Editor (PE) | Components of the construct | Mechanism involved | Additional features |
|---|---|---|---|---|
| 1 | PE1 | Cas9 H840A nickase + WT Maloney Murine leukemia virus RT enzyme | Cas9 H840A nickase nicks a poynucleotide strand and RT enzyme generates cDNA (copies the pegRNA carrying the construct) restoring the nicked DNA segment | Additionally increased the length of pegRNA. This device proved to be efficient yet there were presence of detectable genome edits |
| 2 | PE2 | PE1 + Pentamutant Reverse Transcriptase Enzyme | Improved version of PE1 in terms of thermostability, affinity of DNA–RNA for the substrates, processing capacity | As it is an improvised version of PE1, it increased the ability of PE1 by almost five folds in efficient prime editing point mutation. Led to strategic incorporation of targeted insertions and deletions |
| 3 | PE3 | An additional gRNA was coupled with pegRNA | gRNA directed Cas9 H840A nickase component of PE1 to nuck genomic DNA at a site near to opposite strand nicked portion | Improved efficiency when Anzalone et al. constructed the pegRNA to bring about mutation in the initial Protospacer Adjacent Motif (PAM) |
Fig. 2Role of Prime Editors (PE1, PE2, PE3)
Fig. 3Statistical representation of cancer types by CDC (2020)
Fig. 4Depicts the flow chart representation of cancer development
Traditional cancer therapies
| Therapeutic strategy | Used in (type of cancer) | Site of action (or mechanism) | Advantages | Side effects | References |
|---|---|---|---|---|---|
| Methotrexate (MTX) (chemotherapy) | Breast cancer | Competitive inhibitor for dihydrofolate reductase leading to accumulation of folate required for purine synthesis for DNA; cell cycle is arrested | Contributed to prolonged remission of neurological symptoms, increase in survivability and quality of life in patients | Acute meningitis, chronic-delayed encephalopathy, radiculitis, myelosuppression and mucositis | [ |
| Brachytherapy (radiation therapy) | Breast Cancer, Prostrate Cancer, Vagina cancer, Cervix cancer, Endometrium, head neck and lung cancer | Delivers precise radiation doses to the tumor from the inside out in cells that are in M phases and G2 phases that are particularly sensitive to radiation | Radiation dose delivered to the tumor and adjacent tissues is highly conformal and hence reduces the surrounding structure/organ exposure | Long term efficiency and safety issues and may cause collateral radiation exposure to healthy tissue of medical staff | [ |
| CTLA-4 based immunotherapy (immunotherapy) | Prostate cancer | Ipilimumab- a fully human monoclonal antibody that decreases the binding of CTLA-4 to B7 this increases antitumor immunity | When combined with prostate cancer vaccines, Ipilimumab appears even more beneficial for the patients | Not any as such | [ |
| Tamoxifen hormone therapy (hormone therapy) | Breast cancer | Estrogen agonists, antagonists or both, depending on the tisular target | Effects are continued after treatment termination and is independent in additive to chemotherapy | Side effects are associated with endometrium neoplasm, uterine sarcoma and the thromboembolic risks | [ |